Abu Dhabi: The Health Services Company (SEHA) has launched Esketamine nasal spray to treat and manage severe depression in adults who have tried many conventional antidepressant therapies but seen no benefit.
Esketamine binds to receptors in the brain that are different from those which were targeted by antidepressants in the past. It has shown a good safety profile and tolerability in patients.
SEHA has developed this breakthrough therapy for patients suffering from treatment-resistant depression, in keeping with the network’s mission to provide world-class medical care to patients. It will be given as a nasal spray in AHS psychiatry clinics and SKMC and AAH psychiatry outpatient clinics under physician supervision.
Dr. Nahida Niaz Ahmed, Consultant Psychiatrist and Chair of Behavioural Health Council at the organization observed that, “At SEHA, our goal has always been to provide our patients with the highest standards in treatment. Our team of highly experienced psychiatrists and psychologists strive to deliver a holistic and integrated treatment modality, tailored for each patient. Mental health and its treatment differ from patient to patient, which is why we are pleased to add another treatment method to our services, giving us more bandwidth to explore treatment solutions that are as tailored to each patient as possible.”
A number of patients recently shared their experiences with Esketamine after receiving therapy, emphasizing how it helped their recovery.
Many patients struggling with major depressive disorders who used anti-depressant medications and even shock treatments were never relieved. But after a month of using the nasal spray, they began to notice positive changes in lifestyle and social interacting and staying motivated.
Some patients even with suicidal tendency have gradually been able to deal with negative thoughts and replaced them with goals and ambitions for a better future after using the nasal spray.
Most Read: COVID-19 shifts consumer behavior in food consumption